| PHARMACEUTICAL-BIOTECHNOLOGY-AND-MEDICAL-DEVICE- |
PHARMACEUTICAL-BIOTECHNOLOGY-AND-MEDICAL-DEVICE- |
92%
|
BLS Pharmaceutical, biotechnology and medical device companies 9 % 9 % 4 % 22 % 10 % 9 % 4 % 23 % Total revenues 87 % 9 % 4 % 100 % 87 % 9 % 4 % 100 % |
| LABCORP-RECEIVABLES |
LABCORP-RECEIVABLES |
85%
|
collections from the receivables in excess of amounts required to repay the Purchasers and other creditors of Labcorp Receivables may be remitted to the Company |
| PARKVIEW-HEALTH-SYSTEM-INC |
PARKVIEW-HEALTH-SYSTEM-INC |
85%
|
quisitions $ 165.0 $ 37.2 $ — $ 202.2 Intangible assets recognized from business acquisitions that closed during the three months ended March 31, 2026, including any related measurement period adjust… |
| FTRE |
Fortrea Holdings Inc. |
72%
|
Reciprocal relationship from FTRE graph: Reciprocal relationship from LH graph: ted to the continued impact of COVID-19; and other events beyond the Company's control; 33. discontinuation or recalls … |
| FTRE |
Fortrea Holdings Inc. |
72%
|
ted to the continued impact of COVID-19; and other events beyond the Company's control; 33. discontinuation or recalls of existing products used in the performance of testing; 34. a failure in the Co… |
| TD |
The Toronto-Dominion Bank |
72%
|
Reciprocal relationship from TD graph: Reciprocal relationship from LH graph: Reciprocal relationship from TD graph: Reciprocal relationship from LH graph: Reciprocal relationship from TD graph: Reci… |
| TD |
The Toronto-Dominion Bank |
72%
|
edit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers and the Company is required to ma… |
| BAYSTATE-MEDICAL-CENTER-PROVIDENCE-MEDICAL-FOUND |
BAYSTATE-MEDICAL-CENTER-PROVIDENCE-MEDICAL-FOUND |
62%
|
risk for specific biotechnology receivable balances. F-19 Index LABCORP HOLDINGS INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Dollars and shares in millions, except per share dat… |
| BEACON-LABORATORY-BENEFIT-SOLUTIONS-INC |
BEACON-LABORATORY-BENEFIT-SOLUTIONS-INC |
62%
|
$ 423.3 Dispositions During the year ended December 31, 2024, the Company sold the assets of its Beacon Laboratory Benefit Solutions, Inc. for $ 13.5 and recorded a gain of $ 6.4 . F-20 Index LABCORP… |
| FACEBOOK-IRELAND-LIMITED |
FACEBOOK-IRELAND-LIMITED |
62%
|
an inspection report documenting the deficiencies and setting deadlines for any required corrective actions. The USDA may impose fines, suspend and/or revoke licenses and registrations, or confiscate… |
| MUFG-BANK-LTD |
MUFG-BANK-LTD |
62%
|
edit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers and the Company is required to ma… |
| PRELIMINARY-PERSONAL-GENOME-DIAGNOSTICS-INC |
PRELIMINARY-PERSONAL-GENOME-DIAGNOSTICS-INC |
62%
|
— — — — — ( 2.3 ) ( 2.3 ) Other liabilities — — — — — ( 4.1 ) — ( 4.1 ) Total liabilities acquired — — 3.9 — — ( 1.7 ) ( 10.6 ) ( 8.4 ) Net assets acquired $ 110.2 $ 112.8 $ 110.0 $ 157.0 $ 107.7 $ 7… |
| WESTPAC-LABS-INC |
WESTPAC-LABS-INC |
62%
|
risk for specific biotechnology receivable balances. F-19 Index LABCORP HOLDINGS INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Dollars and shares in millions, except per share dat… |
